Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 106,427
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Phone: 888-658-8287
ZacksResearch
ZacksResearch Oct. 6 at 3:39 PM
Pharma ETFs are heating up 💊🔥 A Trump-Pfizer boost is driving fresh momentum, and ETFs like $PPH, $IHE, $PJP & $XPH are looking strong as defensive, undervalued growth plays. See the full 4-reason bull case here 👉 https://www.zacks.com/stock/news/2762423/4-reasons-to-buy-pharma-etfs-now-for-a-healthy-portfolio?cid=sm-stocktwits-2-2762423-teaser-14771&ADID=SYND_STOCKTWITS_TWEET_2_2762423_TEASER_14771
0 · Reply
thewavetrading
thewavetrading Oct. 6 at 3:56 AM
$PPH: This is similar to $XLV. Ideally, a pullback to the 92 zone could present a good opportunity for a long position. $PPH is displaying an inverse head and shoulders (IHS) pattern with a target at 98.90. I need to investigate whether a leveraged +3x ETF is available.
0 · Reply
thewavetrading
thewavetrading Oct. 2 at 12:46 AM
$PPH: Even more impressive is the bullish momentum in the pharmaceutical sector that has broken through the neckline of an inverse head and shoulders pattern. This strong upward movement signals a promising outlook for the #Pharmaceutical Industry.
0 · Reply
goinbananas
goinbananas Oct. 1 at 9:54 PM
$MRK it’s a start! $PPH $SPY $QQQ
0 · Reply
thewavetrading
thewavetrading Oct. 1 at 4:12 AM
$PPH shows a structure similar to $XLV, with a potential Inverse Head and Shoulders formation. It is set to challenge the downtrend line established since the September 2024 high. If it succeeds, the target will be the August 2014 high.
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:22 AM
$BMRN $PPH $PJP $IHE Biomarin Max-Pain inching closer to $60 as more calls get bought... 15% upside?
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:20 AM
$BMRN $IHE $PPH $PJP Biomarin showing inverse head and shoulders... Algos bought it and the price held the algo buying level rather well imo
0 · Reply
fallondpicks
fallondpicks Sep. 30 at 10:25 PM
25 #stockbreakouts $ANAB (gap), $PATH (gap), $PPH (base), $UNFI (gap). Eight sub-$1, two $1-2
0 · Reply
ZacksResearch
ZacksResearch Sep. 26 at 2:13 PM
Trump just nuked Big Pharma with a 100% tariff 💥 Pharma giants took a hit and ETFs like $XPH, $FTXH, $IHE, and $PPH all slid on the news. Full breakdown of the fallout here 👉 https://www.zacks.com/stock/news/2757571/trump-slams-100-tariff-on-imported-drugs-pharma-etfs-take-a-hit?art_rec=home-home-investment_ideas_stocks-ID14-txt-2757571&cid=sm-stocktwits-2-2757571-teaser-14301&ADID=SYND_STOCKTWITS_TWEET_2_2757571_TEASER_14301
0 · Reply
ZacksResearch
ZacksResearch Sep. 26 at 12:50 PM
Trump's 100% pharma tariffs trigger sector upheaval! 📉 💊 Major sell-offs in U.S. Pharma Stocks 📉 Pharma ETFs like $XPH, $FTXH, and $PPH take a hit 🏭 Long-term boost possible, but subject to complexity and delay Impacts and outlook here 👉 https://www.zacks.com/stock/news/2757571/trump-slams-100-tariff-on-imported-drugs-pharma-etfs-take-a-hit?cid=sm-stocktwits-2-2757571-body-14250&ADID=SYND_STOCKTWITS_TWEET_2_2757571_BODY_14250
0 · Reply
Latest News on PPH
Final Trade: JCI, PPH, TOL, IBM

Oct 7, 2025, 6:19 PM EDT - 3 days ago

Final Trade: JCI, PPH, TOL, IBM

IBM JCI TOL


PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest

Sep 18, 2025, 8:52 AM EDT - 23 days ago

PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest


PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

Apr 14, 2025, 9:15 AM EDT - 6 months ago

PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger


Final Trade: MSTR, PPH, TLT, MCD

Jan 7, 2025, 6:37 PM EST - 9 months ago

Final Trade: MSTR, PPH, TLT, MCD

MCD MSTR TLT


PPH: A Strong Fund To Play Big Pharma

Jul 18, 2024, 3:19 PM EDT - 1 year ago

PPH: A Strong Fund To Play Big Pharma


PPH: Ignore The Election Scare, Buy Pharma And Healthcare

Jan 19, 2024, 7:03 AM EST - 1 year ago

PPH: Ignore The Election Scare, Buy Pharma And Healthcare


Healthcare In 2024: Navigating The Biopharma Bull Run

Jan 17, 2024, 11:22 PM EST - 1 year ago

Healthcare In 2024: Navigating The Biopharma Bull Run

FHLC IBB IYH VHT XBI XLV


Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

Nov 16, 2023, 2:00 AM EST - 2 years ago

Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.

BMY JNJ LLY PFE


Biotech Stocks Are Rallying, but the Outlook Isn't Good

Nov 15, 2023, 12:28 PM EST - 2 years ago

Biotech Stocks Are Rallying, but the Outlook Isn't Good

XBI XLV


How The Pharmaceutical Industry Is Using AI

May 14, 2023, 3:56 AM EDT - 2 years ago

How The Pharmaceutical Industry Is Using AI

AZN JNJ MSFT NVS


PPH Fell As Much As The Market Despite Resilience

Mar 24, 2023, 3:49 PM EDT - 2 years ago

PPH Fell As Much As The Market Despite Resilience


Betting On Biotech

Feb 10, 2023, 10:02 AM EST - 2 years ago

Betting On Biotech

DVA MRNA


PPH Might Be Too Safe For A Recovering Market

Jan 13, 2023, 5:28 PM EST - 2 years ago

PPH Might Be Too Safe For A Recovering Market


Can Health Care Stocks Outperform Again In 2023?

Jan 11, 2023, 6:09 PM EST - 2 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG ARKG BBC BBH BBP BMED CNCR


PPH Investors Should Keep On Top Of Regulatory Developments

Aug 26, 2022, 8:00 AM EDT - 3 years ago

PPH Investors Should Keep On Top Of Regulatory Developments


PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return

Apr 13, 2022, 2:45 PM EDT - 3 years ago

PPH: A Pharmaceutical ETF Delivering Close To 10% Total Return


Pharma In Transition: Context And Opportunities

Mar 28, 2022, 2:32 PM EDT - 3 years ago

Pharma In Transition: Context And Opportunities

FTXH GSK JNJ PILL PJP SNY XPH


ZacksResearch
ZacksResearch Oct. 6 at 3:39 PM
Pharma ETFs are heating up 💊🔥 A Trump-Pfizer boost is driving fresh momentum, and ETFs like $PPH, $IHE, $PJP & $XPH are looking strong as defensive, undervalued growth plays. See the full 4-reason bull case here 👉 https://www.zacks.com/stock/news/2762423/4-reasons-to-buy-pharma-etfs-now-for-a-healthy-portfolio?cid=sm-stocktwits-2-2762423-teaser-14771&ADID=SYND_STOCKTWITS_TWEET_2_2762423_TEASER_14771
0 · Reply
thewavetrading
thewavetrading Oct. 6 at 3:56 AM
$PPH: This is similar to $XLV. Ideally, a pullback to the 92 zone could present a good opportunity for a long position. $PPH is displaying an inverse head and shoulders (IHS) pattern with a target at 98.90. I need to investigate whether a leveraged +3x ETF is available.
0 · Reply
thewavetrading
thewavetrading Oct. 2 at 12:46 AM
$PPH: Even more impressive is the bullish momentum in the pharmaceutical sector that has broken through the neckline of an inverse head and shoulders pattern. This strong upward movement signals a promising outlook for the #Pharmaceutical Industry.
0 · Reply
goinbananas
goinbananas Oct. 1 at 9:54 PM
$MRK it’s a start! $PPH $SPY $QQQ
0 · Reply
thewavetrading
thewavetrading Oct. 1 at 4:12 AM
$PPH shows a structure similar to $XLV, with a potential Inverse Head and Shoulders formation. It is set to challenge the downtrend line established since the September 2024 high. If it succeeds, the target will be the August 2014 high.
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:22 AM
$BMRN $PPH $PJP $IHE Biomarin Max-Pain inching closer to $60 as more calls get bought... 15% upside?
0 · Reply
Thamb19
Thamb19 Oct. 1 at 1:20 AM
$BMRN $IHE $PPH $PJP Biomarin showing inverse head and shoulders... Algos bought it and the price held the algo buying level rather well imo
0 · Reply
fallondpicks
fallondpicks Sep. 30 at 10:25 PM
25 #stockbreakouts $ANAB (gap), $PATH (gap), $PPH (base), $UNFI (gap). Eight sub-$1, two $1-2
0 · Reply
ZacksResearch
ZacksResearch Sep. 26 at 2:13 PM
Trump just nuked Big Pharma with a 100% tariff 💥 Pharma giants took a hit and ETFs like $XPH, $FTXH, $IHE, and $PPH all slid on the news. Full breakdown of the fallout here 👉 https://www.zacks.com/stock/news/2757571/trump-slams-100-tariff-on-imported-drugs-pharma-etfs-take-a-hit?art_rec=home-home-investment_ideas_stocks-ID14-txt-2757571&cid=sm-stocktwits-2-2757571-teaser-14301&ADID=SYND_STOCKTWITS_TWEET_2_2757571_TEASER_14301
0 · Reply
ZacksResearch
ZacksResearch Sep. 26 at 12:50 PM
Trump's 100% pharma tariffs trigger sector upheaval! 📉 💊 Major sell-offs in U.S. Pharma Stocks 📉 Pharma ETFs like $XPH, $FTXH, and $PPH take a hit 🏭 Long-term boost possible, but subject to complexity and delay Impacts and outlook here 👉 https://www.zacks.com/stock/news/2757571/trump-slams-100-tariff-on-imported-drugs-pharma-etfs-take-a-hit?cid=sm-stocktwits-2-2757571-body-14250&ADID=SYND_STOCKTWITS_TWEET_2_2757571_BODY_14250
0 · Reply
DFWxplorer
DFWxplorer Sep. 18 at 12:41 PM
$RAYA & $PPH! Money makers for the patient ones!
0 · Reply
SirBank
SirBank Sep. 10 at 4:43 PM
$TOP $SMX $NXTT $PPH $ELPW So far It's been a lucrative day!
1 · Reply
healthcareguru
healthcareguru Aug. 22 at 6:25 PM
$RCKT dramatic laggard in a ripping tape! Tells you the pump is GAME OVER. I warned you…it’s a bleeder now…enjoy that imminent >50% DILUTION, suckers!! 😂👎🐺 $XLV $IWM $PPH
0 · Reply
ZacksResearch
ZacksResearch Aug. 19 at 11:18 AM
$NVO just scored a historic FDA win ✅ Wegovy is now the first GLP-1 approved for MASH, sending shares up 5% and opening the door beyond obesity & diabetes. 📈 ETFs loaded with NVO like $OZEM, $THNR, and $PPH stand to gain. See the full ETF impact here 👉 https://www.zacks.com/stock/news/2734231/nvo-wins-fda-approval-for-mash-treatment-etfs-likely-to-gain?cid=sm-stocktwits-2-2734231-teaser-8260&ADID=SYND_STOCKTWITS_TWEET_2_2734231_TEASER_8260
1 · Reply
TalkMarkets
TalkMarkets Aug. 9 at 6:40 PM
ETFs In Focus On Eli Lilly's Solid Q2 Earnings, Weak Obesity Data $LLY $IHE $PPH $MEDX $OZEM https://talkmarkets.com/content/etfs/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?post=514413&userid=123969
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 3:24 PM
$LLY drops hard after strong Q2 — is this the dip to buy? Solid earnings weren’t enough to offset weak obesity drug data, sending shares lower. But top-exposed ETFs like $IHE, $PPH, $MEDX and $MEDI could offer upside. Find out what makes these ETFs worth a closer look 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-teaser-6913&ADID=SYND_STOCKTWITS_TWEET_2_2684363_TEASER_6913
0 · Reply
ZacksResearch
ZacksResearch Aug. 8 at 2:21 PM
$LLY plunges 14% on disappointing weight-loss pill data despite crushing Q2 earnings! 📉 Eli Lilly beat both top and bottom line estimates, with a 61% EPS jump and a 38% revenue surge. Yet, disappointing weight-loss pill data overshadowed its strong performance and raised FY outlook. Is this a buying opportunity? Check the ETFs like $IHE, $PPH, $OZEM with big LLY exposure here 👉 https://www.zacks.com/stock/news/2684363/etfs-in-focus-on-eli-lillys-solid-q2-earnings-weak-obesity-data?cid=sm-stocktwits-2-2684363-body-6878&ADID=SYND_STOCKTWITS_TWEET_2_2684363_BODY_6878
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 29 at 9:27 AM
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers $AZN $PPH $VTI https://stocktwits.com/news/equity/markets/astrazeneca-q2-beats-on-cancer-drug-sales-maintains-guidance-shares-rise-premarket/cho9ppoR5U0
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 21 at 4:19 PM
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided $MRK $PPH $PJP https://stocktwits.com/news/equity/markets/merck-blockbuster-drug-keytruda-gets-canadian-regulator-approval-for-treating-cervical-cancer/ch8AilFR5rS
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 5:04 PM
$JNJ just lifted its 2025 outlook AND hiked its dividend 💥 A strong Q2 earnings beat is now fueling upside momentum in key healthcare ETFs like $IHE, $PPH, $XLV, and $IYH. See which ETF setups look strongest here 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-teaser-2421&ADID=SYND_STOCKTWITS_TWEET_2_2588884_TEASER_2421
0 · Reply
ZacksResearch
ZacksResearch Jul. 17 at 2:06 PM
$JNJ rallies 6.1% post-earnings beat — should you jump in? 🚀 📈 EPS of $2.77 beats estimates, revenue up 5.8% from the prior year 🔄 Raised FY 2025 guidance & dividends, reduced expected tariff impact to $200 million from $400 million Discover ETFs like $IHE, $PPH, $XLV and $IYH to ride JNJ's growth wave 👉 https://www.zacks.com/stock/news/2588884/etfs-to-gain-on-jnjs-solid-q1-earnings-upbeat-outlook?cid=sm-stocktwits-2-2588884-body-2280&ADID=SYND_STOCKTWITS_TWEET_2_2588884_BODY_2280
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 11 at 3:37 PM
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report $IHE $PPH $PJP https://stocktwits.com/news/equity/markets/fda-may-fast-track-new-drug-reviews-in-return-for-companies-lowering-drug-prices-report/ch8cizDR5ZU
0 · Reply